Explore how DNOW's (DNOW) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

US stock futures (ES=F, NQ=F, YM=F) slip Wednesday morning after top chip stocks pushed the S&P 500 (^GSPC) to close at a record high yesterday. Meta Platforms (META) stock also snapped its 20-day winning streak on Tuesday. President Trump unveiled a fresh batch of 25% tariffs on cars, semiconductors, and pharmaceutical imports that could come as late as April, alongside his proposed reciprocal tariffs and paused plans for a 25% levy on goods from Canada and Mexico, pending negotiations. Investors also await the release of the Federal Reserve's January FOMC meeting minutes and what they could signal about central bank officials' stance on interest rates. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here. This post was written by Luke Carberry Mogan.

Wingstop (WING) delivered earnings and revenue surprises of 2.33% and 1.61%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

ANET's top line benefits from steady customer growth across several end markets. Its focus on product innovation and AI integration is another tailwind.

If you buy and hold a stock for many years, you'd hope to be making a profit. But more than that, you probably want to...

Here's an in-depth look at two longtime Berkshire Hathaway-held stocks.

Despite record-breaking profits, Etsy faces slowing sales and shifting consumer trends. Can its AI-driven strategy turn things around?

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

CULVER CITY, Calif., February 19, 2025--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA) has authorized an expanded access program (EAP) that will bring a vital alternative source of BCG, a standard-of-care medicine in bladder cancer, to patients in the U.S.